Inozyme Pharma Inc (INZY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2020 | 12-2019 | 09-2019 | 06-2019 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -7,738 | -19,724 | -13,180 | -9,144 |
| Depreciation Amortization | -21 | 12 | 17 | 38 |
| Accounts payable and accrued liabilities | 668 | N/A | -441 | -393 |
| Other Working Capital | 1,365 | 601 | -515 | -1,126 |
| Other Operating Activity | -539 | 301 | 629 | 452 |
| Operating Cash Flow | $-6,265 | $-18,810 | $-13,490 | $-10,173 |
| Cash Flows From Investing Activities | ||||
| Change In Deposits | -3,307 | N/A | -2,599 | -3,546 |
| PPE Investments | -101 | -139 | -122 | -43 |
| Other Investing Activity | 0 | -8,252 | 0 | 0 |
| Investing Cash Flow | $-3,408 | $-8,391 | $-2,721 | $-3,589 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 5 | N/A | 63 | 34 |
| Other Financing Activity | 0 | 22,970 | 22,898 | 22,898 |
| Financing Cash Flow | $5 | $22,970 | $22,961 | $22,932 |
| Beginning Cash Position | 31,735 | 35,966 | 35,966 | 35,966 |
| End Cash Position | 22,067 | 31,735 | 42,716 | 45,136 |
| Net Cash Flow | $-9,668 | $-4,231 | $6,750 | $9,170 |
| Free Cash Flow | ||||
| Operating Cash Flow | -6,265 | -18,810 | -13,490 | -10,173 |
| Capital Expenditure | -101 | N/A | -122 | -43 |
| Free Cash Flow | -6,366 | -18,810 | -13,612 | -10,216 |